

Winning Trust Through Quality

Quarterly Report Spetember 2019

CONTENTS

Company Information	2
Directors' Report to the Members	3
Directors' Report to the Members (Urdu)	6
Unconsolidated Condensed Interim Statement of Financial Position	7
Unconsolidated Statement of Profit or Loss and Other Comprehensive Income	8
Unconsolidated Condensed Interim Statement of Changes In Equity	9
Unconsolidated Condensed Interim Statement of Cash Flows	10
Selected Notes to the Unconsolidated Condensed Interim Financial Statements	11
Consolidated Condensed Interim Financial Statements	25

Board of Directors

Mr. Adnan Asdar Ali (Chairman) Mr. Rashid Abdulla Mr. S. Nadeem Ahmed (Chief Executive Officer) Mr. Zubair Razzak Palwala Mr. Ayaz Abdulla Mr. Asad Abdulla Mrs. Shaista Khaliq Rehman

Board of Audit Committee

Mrs. Shaista Khaliq Rehman (Chairperson) Mr. Adnan Asdar Ali (Member) Mr. Asad Abdulla (Member)

Board of HR & Remuneration Committee

Mrs. Shaista Khaliq Rehman (Chairperson) Mr. Adnan Asdar Ali (Member) Mr. Ayaz Abdulla (Member) Mr. Asad Abdulla (Member)

Chief Financial Officer

Mr. Mobeen Alam

Company Secretary

Mr. Zubair Razzak Palwala

Auditors

A. F. Ferguson & Co.

Legal Advisors

Mohsin Tayebaly & Co.

Bankers

Albaraka Bank (Pakistan) Limited Bank Al Habib Limited Bank Alfalah Limited Bank of Punjab Dubai Islamic Bank Pakistan Limited Faysal Bank Limited Habib Bank Limited Habib Metropolitan Bank Limited MCB Bank Limited McB Bank Limited National Bank of Pakistan Silk Bank Limited Soneri Bank Limited Standard Chartered Bank (Pakistan) Limited Summit Bank Limited

Registered Office

First Floor, N.I.C.L. Building, Abbasi Shaheed Road, Off: Shahrah-e-Faisal, Karachi.

Share Registrar

CDC Share Registar Services Limited Head Office, CDC House, 99-B, Block 'B' S.M.C.H.S., Main Shahrah-e-Faisal Karachi - 74400

DIRECTORS' REPORT TO THE MEMBERS

We are pleased to present the unconsolidated interim financial information of your Company for the three months ended September 30, 2019. These financial statements have been prepared in accordance with the requirements of the International Accounting Standard (IAS) 34 – 'Interim Financial Reporting' and the provisions of the directives issued under the Companies Act, 2017.

MARKET OVERVIEW

Pharmaceutical sales in Pakistan grew at a (2013-19) CAGR of 12%, driven by new molecule introductions and supported by underlying demographic trends of increasing affordability, rising population, higher life expectancy and increased incidence of chronic diseases. However, the pharmaceutical industry is experiencing a constant downward trend, due to high reliance of imported APIs, low per capita expenditure and low prices in terms of global environment.

The recent economic conditions have raised challenges on the industry as a whole. It is well known fact that the chemical industry of Pakistan has capacity constraints to develop basic components required for manufacturing drugs. Therefore, the industry resorts to import of raw materials. Due to this significant dependability, fluctuation in exchange rates coupled with stiff price regulations directly affect the product margins and consequent commercial feasibility. Pakistani rupee has experienced double-digit depreciation which has put the pharma industry under immense pressure.

	Septem 2019	n ber 30, 2018	8	
		thousand)	7	48%
Revenue	4,062,321	3,476,142	6 SU0 5	33%
Cost of sales	(2,095,753)	(2,314,234)	Suoillion S	
Gross Profit	1,966,568	1,161,908	5	
Operating expenses Other operating expenses	(1,201,073) (57,658)	(982,431) (46,478)	2 1 0	
Other income Profit from operations Finance cost	151,784 859,621 (135,260)	732,534 865,533 (97,762)	0	2019 2018 Revenue
Profit before tax Income tax expense Profit after taxation	724,361 (177,044) 547,317	(37,979) 729,792		Cost of sales Gross Profit

OPERATING RESULTS

Searle is a Company that has always focused on improving the lives of patients by offering quality healthcare solutions. We have built a firm growing position by putting the benefit of patients and stakeholders, our fundamental priority and are proud of the impact of our efforts.

During the period ended September 30, 2019, the company's financial performance was affected by the exchange rate fluctuations. However, despite the challenging economic conditions, Searle managed to continue its momentum.

Financial highlights are summarized below:

- Net sales of the Company grew by 17% to Rs 4.06 billion.
- Gross profit margin increased to 48%.
- Operating profit margin was 21%
- Profit before and after taxation was 18% and 13% respectively.

EARNINGS PER SHARE

Basic earnings per share after taxation for the period was Rs. 2.58 (2018: Rs. 3.44).

There is no dilution effect on the basic earnings per share of the Company, as the Company has no convertible dilutive potential ordinary shares outstanding as at September 30, 2019.

FUTURE OUTLOOK

In the local market, the therapeutic areas which Searle has over the years strengthened include cardiovascular, cold & cough, diabetes, infant formula, pro-biotic and antibiotics. Moving forward, we are focusing on enhancing the share of specialty generic branded portfolio and targeting differentiated products. It is also pertinent to mention that Searle has an organic pipeline of over 200 products in different stages of the regulatory approval process.

Further, due to overly regulated drug pricing mechanism, volatility in retail prices is a concern of paramount importance for us. Delays in new product approvals also pose key threats for the industry as a whole. However, with the change in recent political scenario, we will have to wait to assess the future economic trends and modify our strategies accordingly. For the longer run, Searle is focusing on emerging portfolios including, bio-similars, medical devices, nutraceuticals and genome sciences.

ACKNOWLEDGEMENT

At Searle, we all are emotionally motivated and willing to contribute enthusiastically on continuous basis. Same is the case with our partners, suppliers and customers, for which we are thankful and expect the same zeal and zest for future contribution. We assure, Searle will continue to work hard to provide long term sustainable growth to everyone associated with us.

For and on behalf of the Board

Syed Nådeem Ahmed Chief Executive Officer

Karachi : October 28, 2019

Zubair Razzak Palwala Director

30 سیبر 2019 کوختم ہونے والی سہ ماہی کے دوران کمپنی کی مالیاتی کارکردگی زرمبادلہ کے نرخوں میں اُ تار چڑھاؤکے باعث متاثر ہوئی تاہم تنصن اور چیلجنگ اقتصادی صورتحال کے باوجود سرل نے اپنا کاروبار بھر پورطریقے پر جاری رکھا۔

مالیاتی نکات مختفرا ذیل میں بیان کئے گئے ہیں

- کمپنی کی خالص سیلز 17 فیصد تک بڑھ کر 4.06 بلین روپے ہوگئی۔
 - مجموعی منافع کې شرح48 فیصد پر بیر قرارر ہی۔
 - آ پریڈیگ منافع کی شرح 21 فیصد تھی۔
- منافع قبل ازاور بعداز شیسیشن بالتر تیب 18 فیصد اور 13 فیصد رہا۔

آمدنى فيشيئر

بنیادی آ مدنی اس مدت کیلئے فی شیئر بعدار ٹیکشین 2.58رو پے رہی (2018: 3.44 روپے)۔ سمپنی کی بنیادی آ مدنی فی شیئر پر براہ راست کو کی اثر ات خاہر نہیں ہوئے کیونکہ کمپنی کے سی مکامنہ تنظی کی طاقت کی حامل نہ ہونے کے باعث عمومی شیئرز برطابق 30 ستمبر 2019 برقر اررہے۔

مستغتل يرايك نظر

مقامی مارکیٹ میں ان چیدہ چیدہ شعبوں جہاں سرل نے چند سالوں میں اینحکام حاصل کیا ہے بالحضوص کارڈیو دیںکولر، نزلہ ادرکھانمی ، ذیابطیس ، شیرخوار فارمولا، پرو۔یا ئیونک ادرایڈی بائیونکس میں اس کی پوزیشن بہت متحکم ہے۔آ گے بڑھتے ہوئے ہم خصوصاً عمومی برانڈز کے پورٹ فولیو میں شیئر بڑھانے اور مختلف النوع پروڈ تکش کوٹارگٹ کررہے ہیں۔ بیداضح کرنا بھی ضروری ہے کہ سرل 200 سے زائد آرگینک مصنوعات کور یکولیٹری منظوری کے محلف مراحل کے عمومی طریقہ کار رکھ کر رہا ہے۔

مزید برآں ادویات کے نرخوں کے غیر منظم میکنزم کے باعث ریٹیل نرخوں میں اتار چڑھاؤ بھی ہمارے لئے تشویش کا ایک بڑا سبب ہے۔ نگ پروڈ کٹ کی منظوری میں تاخیر سے بھی چموق طور پرصنعت کے لئے کلیدی خطرات سامنے آتے ہیں۔ تاہم جالیہ ساسی صورتحال کی تید یلی کے ساتھ ہم آنے والے معاش ربحانات کا جائزہ لے رہے ہیں اور اس کے مطابق اپنی حکمت عملیوں میں تبدیلی لا نمیں گے۔ آنے والے سالوں میں سرل اکبر تے ہوئے پورٹ فولیوشمول بائیو۔ سمیلرز، میڈیکل ڈیواکسز ، نیوٹراسیوٹیکٹز اورجنیوم سائنسز پرخصوصی توجہ دے رہی ہے۔ **اظہار تشکر**

سرل میں ہم سب جذباتی طور برطحوظ و متحرک بیں اور مستقل بنیا دوں پر پُر عزم شراکت کے خواہ شند ہیں۔ اسی طرح ہمارے شراکت کار، سپلائرز اور صارفین، جس کیلئے ہم ان کے شکر گزار ہیں اور توقع کرتے ہیں کہ ای گنن کے ساتھ وہ مستقبل میں بھی شریک کارر ہیں گے۔ ہم یقین دبانی کراتے ہیں کہ سرل اپنی انتہائی کوششیں جاری رکھے گی اور ہم سے مسلک تمام شراکت کاروں کے لئے طویل مدتی بنیا دوں پر ترقی کی نئی منازل فراہم کی جائیں گی۔

(Luhar Galuale) ز بيررزاق پالُوالا ڈائر یکٹر



کراچی: ۲۸ اکتوبر ۱۰۹ء

5

ڈ ائر یکٹرز کی رپورٹ


ہم 30 ستمبر 2019 کو ختم ہونے والی 3 ماہ کی مدت کیلئے کمپنی کے غیر مجموعی عبوری مالیاتی معلومات پیش کرتے ہوئے خوشی محسوں کرتے ہیں۔ یہ مالیاتی حسابات انٹریشنل اکاؤ منٹک اسٹینڈرڈ (IAS)34 - 'عبوری فنانشل رپورٹنگ' کی شرائط وضوائط اوکیلینزا یک 2017 کے تحت جاری کردہ ہدایات کی شقوں کے مطابق تیار کئے گئے ہیں۔

ماركيث كاجائزه

پاکستان میں فارماسیونیکٹر کی فروخت (19-2013) میں 12 فیصد کے CAGR تک بڑھیں چس کی وجہ نے مالیکیو ل کا تعارف اوراستطاعت میں اضافے کے رجمانات، بڑھتی ہوئی آبادی، بلندتر زندگی کے امکانات اورمہلک و پیچیدہ امراض میں اضافہ تھا۔ اس کے باوجود فارماسیوٹیکل کی صنعت مستقل طور پر نیچلر بتحان سے گزررہی ہے جس کی وجہ درآ مدکر دہ APIs پرزیادہ انحصار، فی کس اخراجات میں کمی اورعالمی ماحول کی سطح پر کمتر نرخ ہیں۔

حالیہ اقتصادی صورتحال نے مجموع طور پرصنعت کے لئے چیلیجر کھڑ ہے کئے ہیں۔ جبیہا کہ ہم جانتے ہیں کہ پاکستان کی تیمیکل انڈسٹر کی ادویات کی تیاری کے لئے درکار بنیا دی اجزاء تیار کرنے کی گنجائش کی حال نہیں ہے لہٰذاصنعت کوخام مال کی درآ مد براخصار کرنا پڑتا ہے۔ اس اخصار کی وجہ سے زرمبادلہ کی نرخوں میں اُتار چڑھاؤ کے ساتھ نرخوں کی سخن ریگولیشٹز براہِ راست پروڈ کٹ سے شرح منافع اور بعدازاں تجارتی افادیت کو متا ژ کرتی ہیں۔ پاکستانی روپے کی قد رحالیہ دنوں میں دوہندسوں میں کم ہوئی جس سے فار ماانڈ سٹر کی کو محت مان کو ارزان پڑتا ہے۔

آيرينىڭ نتائج



	2019	2018
	(روپے ہزار	روں میں)
آ مدنی	4,062,321	3,476,142
فروخت کے اخراجات	(2,095,753)	(2,314,234)
محموعي آمدني	1,966,568	1,161,908
آ پریٹنگ اخراجات	(1,201,073)	(982,431)
ديگرآ پريڻنگ اخراجات	(57,658)	(46,478)
ديگرآ مدنی	151,784	732,534
آ پریشنز سے آمدنی	859,621	865,533
مالياتى اخراجات	(135,260)	(97,762)
منافع قيل ازشكس	724,361	767,771
ائكم نيكس اخراجات	(177,044)	(37,979)
منافع يعداز فيكسيشن	547,317	729,792

30 ستبر

UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION AS AT SEPTEMBER 30, 2019

		(Un-audited) September 30, 2019	(Audited) June 30, 2019
ASSETS	Note	(Rupees ii	1 '000)
Non-current assets			
Property, plant and equipment Investment properties - at cost Intangible assets Long-term investments - subsidiaries Long-term loans Long-term deposits	5 6	2,882,606 2,504,676 153,866 1,686,186 258 7,996 7,024,099	2,879,439 2,458,041 164,913 1,686,186 270 7,396 7,100,245
Current assets		7,234,988	7,196,245
Inventories Trade receivables Loans and advances Trade deposits and short-term prepayments Other receivables Taxation - payments less provision Tax refunds due from Government - Sales Tax Cash and bank balances	7 8 9	2,420,833 5,638,620 4,538,065 94,831 2,269,130 1,004,034 13,013 7,366	2,194,650 4,866,132 4,516,941 81,882 3,077,649 1,128,345 35,179 204,547
		15,985,892	16,105,325
Total assets		23,220,880	23,301,570
EQUITY AND LIABILITIES			
EQUITY			
Share capital Unappropriated profit General reserve Share premium Revaluation surplus on property, plant and equipment	10	2,124,253 9,981,065 280,251 1,630,974 <u>1,048,679</u> 15,065,222	2,124,253 9,431,627 280,251 1,630,974 1,050,800 14,517,905
LIABILITIES			
Non-current liabilities Deferred tax liabilities Employee benefit obligations Current liabilities		93,239 57,164 150,403	93,240 55,820 149,060
			1.500.400
Trade and other payables Borrowings Unpaid dividend Unclaimed dividend	11 12 13	4,280,094 3,574,812 112,062 38,287	4,529,480 3,954,776 112,062 38,287
Total liabilities		8,005,255	8,634,605 8,783,665
Contingencies and commitments	14	, ,	
•		23,220,880	23,301,570
Total equity and liabilities			20,001,070

The annexed notes from 1 to 24 form an integral part of these condensed interim financial statements.

Just

Chief Executive Officer

Director

Chief Financial Officer

UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF **PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME** For the period ended September 30, 2019 - Unaudited

		Quarter ended		
		September 2019	September 2018	
	Note	(Rupees	in '000)	
Revenue from contracts with customers	15	4,062,321	3,476,142	
Cost of sales	16	(2,095,753)	(2,314,234)	
Gross profit		1,966,568	1,161,908	
Distribution costs		(927,701)	(769,942)	
Administrative expenses		(273,372)	(212,489)	
Other operating expenses		(57,658)	(46,478)	
Other income	17	151,784	732,534	
Profit from operations		859,621	865,533	
		(135,260)	(97,762)	
Profit before income tax		724,361	767,771	
Income tax expense		(177,044)	(37,979)	
Profit for the period		547,317	729,792	
Other comprehensive income		-	-	
Total comprehensive income		547,317	729,792	
Desig and diluted corpings			(Re-stated)	
Basic and diluted earnings per share (Rupees)	18	2.58	3.44	

The annexed notes from 1 to 24 form an integral part of these condensed interim financial statements.

Just

Chief Executive Officer

Director

Chief Financial Officer

UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY For the period ended September 30, 2019 - Unaudited

		Capital reserves Revenue reserves						
	Share capital	Share premium	Issue of bonus shares	Revaluation surplus on Property, plant & equipment Rupees i	General reserve n '000	Unappro- priated profits	Total reserves	Total
Balance as at July 01, 2018	1,847,177	1,630,974	-	574,331	280,251	7,981,789	10,467,345	12,314,522
Transfer of incremental depreciation for the period (net of deferred tax)	-	-	-	(279)	-	279	-	-
Total comprehensive income for the period	-	-	-	-	-	729,792	729,792	729,792
Balance as at September 30, 2018	1,847,177	1,630,974	-	574,052	280,251	8,711,860	11,197,137	13,044,314
Balance as at July 01, 2019	2,124,253	1,630,974	-	1,050,800	280,251	9,431,627	12,393,652	14,517,905
Transfer of incremental depreciation for the period (net of deferred tax)		-	-	(2,121)	-	2,121	-	
Total comprehensive income for the period				-	-	547,317	547,317	547,317
Balance as at September 30, 2019	2,124,253	1,630,974	-	1,048,679	280,251	9,981,065	12,940,969	15,065,222

The annexed notes from 1 to 24 form an integral part of these condensed interim financial statements.

flerof.

Chief Executive Officer

a natural

Director

Chief Financial Officer

UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF **CASH FLOWS** For the period ended September 30, 2019 - Unaudited

CASH FLOWS FROM OPERATING ACTIVITIES	Note	September 30, 2019 (Rupees	September 30, 2018 in '000)
Cash generated from operations Finance cost paid Income taxes paid Decrease in long-term loans	19	433,885 (91,843) (52,734) 12	(22,044) (75,751) (86,382) 28
Net cash generated from operating activities		289,320	(184,149)
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment Proceeds from disposal of property, plant and equipmer Purchase of investment properties Purchase of intangibles	nt	(47,721) 2,450 (61,266) -	(176,096) - (2,520) (12,441)
Net cash used in investing activities		(106,537)	(191,057)
CASH FLOWS FROM FINANCING ACTIVITIES			
Dividend paid		-	(3)
Net cash used in financing activities			(3)
Net increase / (decrease) in cash and cash equivalents		182,783	(375,209)
·		,	
Cash and cash equivalents at the beginning of the period		(3,340,229)	(2,186,442)
Cash and cash equivalents at the end of the period	20	(3,157,446)	(2,561,651)
		(3,157,446)	(2,561,651)

The annexed notes from 1 to 24 form an integral part of these condensed interim financial statements.

Jurof.

Chief Executive Officer

Director

Chief Financial Officer

NOTES TO THE UNCONSOLIDATED CONDENSED INTERIM FINANCIAL STATEMENTS

For the period ended September 30, 2019 - Unaudited

1. THE COMPANY AND ITS OPERATIONS

1.1 The Searle Company Limited (the Company) was incorporated in Pakistan as a private limited company in October 1965. In November 1993, the Company was converted into a public limited company. Its shares are quoted on the Pakistan Stock Exchange. The Company is principally engaged in the manufacture of pharmaceutical and other consumer products. The registered office of the Company is situated at 1st Floor, N.I.C. Building, Abbasi Shaheed Road, Karachi.

International Brands Limited is the holding company, which holds 56.60% shareholding in the Company.

Following are the subsidiary companies:

	Principal place of business	Effective %age of holding	
Listed Company		September 30, 2019	June 30, 2019
- IBL HealthCare Limited Unlisted Companies		74.19%	74.19%
 Searle Pharmaceuticals (Private) Limited Searle Laboratories (Private) Limited Searle Biosciences (Private) Limited 	Pakistan	100.00% 100.00% 100.00%	100.00% 100.00% 100.00%
 IBL Identity (Private) Limited IBL Future Technologies (Pvt) Limited Nextar Pharma (Private) Limited 		100.00% 100.00% 87.20%	100.00% 100.00% 87.20%

The Company effectively holds 87.20% (June 30, 2019: 87.20%) shareholding in Nextar Pharma (Private) Limited through Searle Biosciences (Private) Limited.

2. BASIS OF PREPARATION

These unconsolidated condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting. The accounting and reporting standards as applicable in Pakistan for interim financial reporting comprise of:

- International Accounting Standard (IAS) 34, Interim Financial Reporting, issued by the International Accounting Standards Board (IASB) as notified under the Companies Act, 2017; and

- Provisions of and directives issued under the Companies Act, 2017

Where the provisions of and directives issued under the Companies Act, 2017 differ with the requirements of IAS 34, the provisions of and directives issued under the Companies Act, 2017 have been followed.

These unconsolidated condensed interim financial statements do not include all the information required for full financial statements and should be read in conjunction with the annual financial statements for the year ended June 30, 2019.

NOTES TO THE UNCONSOLIDATED CONDENSED INTERIM

FINANCIAL STATEMENTS

For the period ended September 30, 2019 - Unaudited

2.1 Changes in accounting standards, interpretations and pronouncements

a) Standards, interpretations and amendments to published approved accounting standards that are effective and relevant

IFRS 9 'Financial instruments' - This standard replaces the guidance in IAS 39. It includes requirements on the classification and measurement of financial assets and liabilities; it also includes an expected credit loss model that replaces the current incurred loss impairment model.

IFRS 15 'Revenue from contracts with customers' - IFRS 15 replaces the previous revenue standards: IAS 18 Revenue, IAS 11 Construction Contracts, and the related interpretations on revenue recognition.

IFRS 15 introduces a single five-step model for revenue recognition and establishes a comprehensive framework for recognition of revenue from contracts with customers based on a core principle that an entity should recognise revenue representing the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

b) Standards, interpretations and amendments to published approved accounting standards that are not yet effective but relevant

The following is the new standard, amendment to existing approved accounting standards and new interpretations that will be effective for the periods beginning on or after July 1, 2019 that may have an impact on the financial statements of the Company.

IFRS 16 'Leases' - IFRS 16 replaces the previous lease standard: IAS 17 Leases. It will result in almost all leases being recognised on the statement of financial position, as the distinction between operating and finance leases is removed. Under the new standard, an asset (the right to use the leased item) and a financial liability to pay rentals are recognised. The only exceptions are short term and low value leases.

Further, IFRS 9 'Financial Instruments' (previously applicable from annual periods beginning on or after July 1, 2018). This standard replaces the guidance in IAS 39. It includes requirements on the classification and measurement of financial assets and liabilities; it also includes an expected credit losses model that replaces the current incurred loss impairment model.

The management is in the process of assessing the impact of changes laid down by these standards on its financial statements.

3. SIGNIFICANT ACCOUNTING INFORMATION AND POLICIES

The accounting policies and method of computations adopted in the preparation of these unconsolidated condensed interim financial statements are the same as those applied in the preparation of the financial statements for the year ended June 30, 2019.

4. ACCOUNTING ESTIMATES AND JUDGEMENTS AND FINANCIAL RISK MANAGEMENT

The preparation of these unconsolidated condensed interim financial statements in conformity with approved accounting standards requires management to make estimates, assumptions and use judgements that affect the application of policies and reported amounts of assets and liabilities and income and expenses. Estimates, assumptions and judgements are continually evaluated and based on historical experience and other factors, including reasonable expectations of future events. Revisions to accounting estimates are recognised prospectively commencing from the period of revision.

Judgements and estimates made by the management in the preparation of these unconsolidated condensed interim financial statements are the same as those that were applied to financial statements as at and for the year ended June 30, 2019.

The Company's financial risk management objectives and policies are consistent with those disclosed in the financial statements as at and for the year ended June 30, 2019.

		(Unaudited) September 30, 2019	(Audited) June 30, 2019
5.	PROPERTY, PLANT AND EQUIPMENT	(Rupees ir	1 '000)
	Operating assets - note 6.1 Capital work-in-progress - at cost	2,783,791 	2,728,713 150,726 2,879,439

5.1 Details of additions in operating assets including transfers from capital work-in-progress during the period are as follows:

	Additions (at cost)			osals ok value)
	September 30, 2019	September 30, 2018 (Bupees	September 30, 2019 s in '000)	September 30, 2018
Building on leasehold land Plant and machinery	43,112 14,928	26,451 128,682	-	-
Furniture & fittings Vehicles	-	399	- (1,058)	-
Office equipment	41,592 99,632	<u> </u>	(1,058)	-

6.	LONG-TERM INVESTMENTS	(Unaudited) September 30, 2019 (Rupees in	(Audited) June 30, 2019 1 '000)
	Subsidiary companies (at cost) - note - 6.1	1,686,186	1,686,186

NOTES TO THE UNCONSOLIDATED CONDENSED INTERIM

FINANCIAL STATEMENTS For the period ended September 30, 2019 - Unaudited

6.1 Subsidiary companies

	(Unaudited) September 30, 2019		(Audited) June 30, 2019		
Listed security	Equity % held	Investment at cost es '000)	Equity % held (Rupee	Investment at cost s '000)	
IBL HealthCare Limited					
40,126,241 (June 30, 2019: 40,126,241) Ordinary shares of Rs. 10 each Market price as at September 30, 2019: Rs. 24.19 (June 30, 2019: Rs. 33.50) per share	74.19%		74.19%	1,300,911	
Unlisted securities		1,300,911		1,300,911	
Searle Pharmaceuticals (Private) Limited					
40,000 (June 30, 2019: 40,000) Ordinary shares of Rs. 10 each Break up value as at September 30, 2019: Rs.48.52 (June 30, 2019: Rs. 48.52) per share	100%	400	100%	400	
Searle Laboratories (Private) Limited					
12,500,000 (June 30, 2019: 12,500,000) Ordinary shares of Rs. 10 each Break up value as at September 30, 2019: Rs.0.94 (June 30, 2019: Rs. 0.94) per share	100%	125,000	100%	125,000	
Searle Biosciences (Private) Limited					
1,000,000 (June 30, 2019: 1,000,000) Ordinary shares of Rs. 10 each Break up value as at September 30, 2019: Rs.19.70 (June 30, 2019: Rs. 12.02) per share	100%	10,000	100%	10,000	
IBL Identity (Private) Limited					
9,500,000 (June 30, 2019: 9,500,000) Ordinary shares of Rs. 10 each Break up value as at September 30, 2019: Rs.Nil (June 30, 2019: Rs. Nil) per share	100%	49,875	100%	49,875	
IBL Future Technologies (Private) Limited 20,000,000 (June 30, 2019: 20,000,000)					
Ordinary shares of Rs. 10 each Break up value as at September 30, 2019: Rs.10 (June 30, 2019: Rs. 10) per share	100%	200,000	100%	200,000	
		1,686,186		1,686,186	
		,,		,,	

Shares held as at September 30, 2019 include 1,117,379 shares (June 30, 2019: 1,117,379 shares) of IBL HealthCare Limited withheld at the time of bonus declaration. The Company has included these shares in its portfolio pending decisions of the Honourable High Court of Sindh on petitions filed by Company in respect of tax on bonus shares.

7.	TRADE RECEIVABLES	(Unaudited) September 30, 2019 (Rupees	(Audited) June 30, 2019 in '000)
	Considered good		
	- Export receivables - secured	439,894	307,294
	- Due from related parties, unsecured - note 7.1	4,339,695	3,839,765
	- others - unsecured	859,031	719,073
	Considered doubtful	5,638,620 152,003	4,866,132 152,003
	Less: Provision for doubtful debts	(152,003)	(152,003)
		5,638,620	- 4,866,132

7.1 These are stated net of amount payable to IBL Operations (Private) Limited, United Brands Limited and IBL Logistics (Private) Limited - associated companies amounting to Rs. 385.53 million (2019: Rs. 284.97 million), Rs. 15.54 million (2019: Rs. 15.36 million) and Rs. 1.01 million (2019: Rs. 1.01 million) respectively.

8. LOANS AND ADVANCES

- **8.1** This includes interest free loan provided to IBL Identity (Private) Limited wholly owned subsidiary amounting to Rs. 3,081.63 million as at September 30, 2019 (June 30, 2019: Rs. 3,046.13 million).
- **8.2** This represents advance to Searle Biosciences (Private) Limited and Searle Laboratories (Private) limited wholly owned subsidiaries amounting to Rs. 972.2 million (June 30, 2019: Rs. 975.6 million), Rs. 11.9 million (June 30, 2019: Rs. 6.5 million) respectively. These advances are provided for the purpose of financial assistance and are settled in the ordinary course of business.

NOTES TO THE UNCONSOLIDATED CONDENSED INTERIM

FINANCIAL STATEMENTS For the period ended September 30, 2019 - Unaudited

9.	OTHER RECEIVABLES	(Unaudited) September 30, 2019 (Rupees	(Audited) June 30, 2019 in '000)
	Receivables from related parties Due from subsidiary companies:		
	- IBL HealthCare Limited - Searle Pharmaceuticals (Private) Limited	32,849	24,777
	against dividend income - Searle Laboratories (Private) Limited	1,018,310 425	1,982,566
	 Searle Biosciences (Private) Limited - note - 9.1 Nextar Pharma (Pvt) Limited against expenses IBL Future Technologies (Private) Limited 	547,646 9,330	399,378 5,414
	against financial assistance	1,949	1,949
	Due from associated companies:	1,610,509	2,414,084
	 IBL Operations (Private) Limited against: mark-up on over due balance & rental income International Brands Limited against expenses rental income International Franchises (Private) Limited against rental income 	31,142 	27,767 7,472 25,538 1,093 61,870
	Due from other related party: - United Retail (SMC-Private) Limited (formerly The Home Makers (SMC-Private)		
	Limited) against rental income	227,195	209,566
	Surplus arising under retirement benefit fund	5,250	5,250
	Receivables from other than related parties Others, considered good - note 9.2	391,486	386,879
		2,269,130	3,077,649

This represent dividends receivable and against expenses from wholly owned subsidiary 9.1 companies.

10. SHARE CAPITAL

11.

Authorised share capital

(Unaudited) September 30, 2019	(Audited) June 30, 2019		(Unaudited) September 30, 2019 (Rupees	(Audited) June 30, 2019 in '000)
300,000,000	300,000,000	Ordinary shares of Rs. 10 each	3,000,000	3,000,000
Issued, subso	cribed and paid	d up capital		
(Unaudited) September 30, 2019 (Number	(Audited) June 30, 2019 of shares)			
12,553,074	12,553,074	Shares allotted for consideration paid in cash	125,531	125,531
24,000	24,000	Shares allotted for consideration other than cash	240	240
199,848,171	199,848,171	Shares allotted as bonus shares	1,998,482	1,998,482
212,425,245	212,425,245		2,124,253	2,124,253
TRADE AND	OTHER PAYAB	LES		
Royalty payabl Accrued liabiliti Payable to prov Advance from Accrued mark- Taxes deducte statutory auth	foreign currenc e vident fund customers - uns up d at source and oorities : Participation Fu	secured payable to	1,457,045 1,035,152 16,503 1,218,510 9,801 34,695 152,890 75,428 188,514 28,798	2,531,434 708,946 23,966 801,222 8,619 22,415 109,473 96,147 149,417 16,342 c1400
Other habilities			62,758 4,280,094	61,499 4,529,480

11.1 This includes amount payable to Searle Pharmaceutical (Private) Limited - wholly owned subsidiary amounting to Rs. 1,099.36 million (June 30, 2019: Rs. 2,192.65 million) on account of toll manufacturing services. This also includes payable to Searle Laboratories (Private) Limited - wholly owned subsidiary amounting to Rs. 9.13 million (June 30, 2019: Rs. 9.13 million).

NOTES TO THE UNCONSOLIDATED CONDENSED INTERIM FINANCIAL STATEMENTS

For the period ended September 30, 2019 - Unaudited

		(Unaudited) September 30, 2019	(Audited) June 30, 2019
12.	BORROWINGS	(Rupees	in '000)
	Secured Running finances under mark-up arrangements - note - 12.1 Export re-finance	3,164,812 210,000	3,544,776 210,000
	Unencounted	3,374,812	3,754,776
	Unsecured Borrowing from IBL Future Technologies (Private) Limited - note 12.2	200,000	200,000
		3,574,812	3,954,776

12.1 The Company has entered into running finance under mark-up arrangements from various banks amounting to Rs. 4,175 million (June 30, 2019: Rs. 4,175 million) which include financing facilities obtained under Islamic mode amounting to Rs. 3,525 million (June 30, 2019: Rs. 3,525 million). The arrangements are secured jointly by registered mortgage of Rs. 589.44 million (June 30, 2019: Rs. 589.44 million) of immovable property together with joint pari passu charge on all current assets of the Company to the extent of Rs. 4,071 million (June 30, 2019: Rs. 4,071 million) in favour of Standard Chartered Bank (Pakistan) Limited (the lead bank).

The rates of mark-up ranged between 13.34% to 13.96% (June 30, 2019: 6.9% to 12.7%) per annum.

12.2 This represents interest free loan obtained from IBL Future Technologies (Private) Limited - wholly owned subsidiary and is repayable on demand.

13. UNPAID DIVIDEND

This includes dividend on bonus shares amounting to Rs. 96.69 million withheld pertaining to 125 shareholders, on which stay from the Honourable High Court of Sindh has been obtained. The amount further includes dividend withheld amounting to Rs. 15.37 million due to non-compliance of certain legal / regulatory requirements by the shareholders.

14. CONTINGENCIES AND COMMITMENTS

14.1 Contingencies

14.1.1 There has been no significant change in the status of contingencies as reported in the note 25 and 33.4 of annual audited financial statements of the Company for the year ended June 30, 2019.

14.2 Commitments

15.

14.2.1 The facility for opening letters of credit and guarantees as at September 30, 2019 amounted to Rs. 2,180 million (June 30, 2019: Rs. 2,111 million) of which the amount remaining unutilised as at period end amounted to Rs. 221 million (June 30, 2019: Rs. 318 million).

14.2.2 Future rentals payable against operating lease arrangement

The Company had entered into lease arrangements with Myplan Pharmaceuticals (Private) Limited and S. A. Pharma, a pharmaceutical concern, respectively, for a period of 20 years for land, building and plant and machinery located at Lahore.

The Company had entered into lease arrangement with First UDL Modaraba for a period of 5 years for land, building and plant and machinery located at Bin Qasim, Karachi.

The details of future rentals over the lease period are as follows:

	(Unaudited) September 30, 2019	(Audited) June 30,
Not later than one year Later than one year but not later than five years Later than five years		2019 in '000) 28,868 137,571 <u>93,959</u> 260,398
REVENUE FROM CONTRACTS WITH CUSTOME		(Unaudited) September 30, 2018 in '000)
Gross sales Local sales Export sales	3,701,258 628,782	3,161,638 488,185
	4,330,040	3,649,823
Toll manufacturing	<u>71,854</u> 4,401,894	<u>87,836</u> 3,737,659
Sales tax	<u>(30,017)</u> 4,371,877	<u>(26,471)</u> 3,711,188
Less:		
Discounts, rebates and allowances Sales return	227,710 81,846	183,007 52,039
	309,556	235,046
	4,062,321	3,476,142

NOTES TO THE UNCONSOLIDATED CONDENSED INTERIM FINANCIAL STATEMENTS For the period ended September 30, 2019 - Unaudited

16. COST OF SALES

This includes inventory written-off during the period amounting to Rs. 6.46 million (September 30, 2018: Rs. 13.6 million)

		September 30, September 30, 2019 2018 (Rupees in '000)	
17.	OTHER INCOME		
	Income from financial assets Dividend income		
	- Searle Pharmaceuticals (Private) Limited - Searle Biosciences (Private) Limited	120,000	607,906 97,696
		120,000	705,602
	Income from non - financial assets		
	Gain on disposal of property, plant and equipment Rental income from investment property Others	1,392 25,033 5,359	- 24,232 2,700
		31,784	26,932
		151,784	732,534
18.	EARNINGS PER SHARE - BASIC AND DILUTED		
	Profit for the period	547,317	729,792
	Weighted average number of ordinary shares in issue during the period (in thousand) - Restated	212,425	212,425
			(Re-stated)
	Earnings per share - Basic and diluted (Rupees)	2.58	3.44

19.	CASH GENERATED FROM OPERATIONS	September 30, September 30, 2019 2018 (Rupees in '000)		
	Profit before income tax	724,361	767,771	
	Add adjustments for non-cash charges and other items Depreciation Gain on disposal of property, plant and equipment Amortisation Provision for retirement benefits obligation Financial cost	58,127 (1,392) 11,047 1,344 135,260	47,055 10,579 900 97,762	
	Profit before working capital changes	928,747	924,067	

Effect on cash flow due to working capital changes

(Increase) / decrease in current assets

20.

Inventories Trade receivables Loans and advances Trade deposits and short-term prepayments Other receivables Sales tax Increase / (decrease) in current liabilities	(226,183) (772,488) (21,124) (12,949) 808,519 22,166 (202,059)	85,644 (791,629) (504,970) (23,241) (27,979) (12,721) (1,274,896)
Trade and other payables	(292,803)	328,785
	(292,803)	328,785
Cash flows generated from operations	433,885	(22,044)
CASH AND CASH EQUIVALENTS		

Cash and bank balances	7,366	19,524
Short term borrowings	(3,164,812)	(2,581,175)
	(3,157,446)	(2,561,651)

NOTES TO THE UNCONSOLIDATED CONDENSED INTERIM

FINANCIAL STATEMENTS For the period ended September 30, 2019 - Unaudited

21. SEGMENT INFORMATION

The financial information regarding operating segments is as follows:

	Pharma	ceutical	Cons	umer	То	tal
	Sept' 30 2019	Sept' 30 2018	Sept' 30 2019 (Rupees	Sept' 30 2018 in '000)	Sept' 30 2019	Sept' 30 2018
Segment revenue	3,693,043	3,073,470	369,278	402,672	4,062,321	3,476,142
Segment result	724,874	132,311	40,621	47,166	765,495	179,477
Unallocated income and expenses						
Other expenses					(57,658)	(46,478)
Other income					151,784	732,534
Finance cost					(135,260)	(97,762)
Profit before taxation					724,361	767,771
Income tax expense					(177,044)	(37,979)
Total comprehensive income					547,317	729,792
	Pharma	ceutical	Cons	umer	То	tal
	Sept' 30 2019	June 30, 2019	Sept' 30 2019 (Rupees	June 30, 2019 in '000)	Sept' 30 2019	June 30, 2019
Segment assets and liabilities						
Segment assets	821,768	836,546	25,594	19,704	847,362	856,250
Unallocated assets					22,373,518	22,445,320
Total assets					23,220,880	23,301,570

8,155,658 8,783,665

8,155,658 8,783,665

Unallocated liabilities Total liabilities

22. TRANSACTIONS WITH RELATED PARTIES

The following transactions were carried out with related parties during the period :

		2019	September 30, 2018
Nature of relationship	Nature of transactions	(Rupees	s in '000)
Holding company	 Corporate service charges Rent income Income from provision of amenities 	60,000 1,669 1,270	48,000 2,276 1,905
Subsidiaries	RevenueOutside processing charges	229,364 -	45,617 873,838
	 Dividend income Short term loan given Advance(received back)/given 	120,000 35,500 (2,900)	705,602 189,950 10,800
Associated companies			
	 Revenue Salaries and wages Purchases Carriage and duties Discounts claimed Rent expense Rent income Stock claims Internet services Architect fee Income from Provision of Amenities Donations Purchases of ERP Hardware Incentive on Searle Focus Prooducts Repair & maintenance Merchandise expense Others 	3,091,743 70 245 1,518 76,265 2,547 16,504 18,778 281 2,375 9,474 4,296 - 696 859 2,203 3,400	2,775,860 130 843 10,512 80,818 1,066 15,268 42,030 1,109 - 1,906 5,300 25,072 1,616 - 18,653
Staff retirement benefits	- Contributions to		
	- Benefits paid	29,213 12,375	26,174 37,429
Key management employees	Colorino and other		
compensation	 Salaries and other employee benefits Contributions to 	41,978	42,090
	Provident Fund - Directors' fees	3,556	4,212 4
	- Sale of goods	24	-

NOTES TO THE UNCONSOLIDATED CONDENSED INTERIM FINANCIAL STATEMENTS

For the period ended September 30, 2019 - Unaudited

22.1 The status of outstanding balances with related parties as at September 30, 2019 is included in the respective notes to the financial statements. These are settled in the ordinary course of business.

23. CORRESPONDING FIGURES

Corresponding figures have been rearranged for better presentation and comparison purpose, wherever considered necessary. However, there is no material reclassification.

24. DATE OF AUTHORISATION FOR ISSUE

These unconsolidated condensed interim financial statements were approved and authorised for issue by the Board of Directors of the Company on October 28, 2019.

Chief Executive Officer

Director

Chief Financial Officer

Consolidated Condensed Interim **Financial** Statements

Contents

Directors' Report to the Members	26
Directors' Report to the Members (Urdu)	29
Consolidated Condensed Interim Statement of Financial Position	30
Consolidated Condensed Interim Statement of Profit or Loss and Other Comprehensive Income	31
Consolidated Condensed Interim Statement of Changes in Equity	32
Consolidated Condensed Interim Statement of Cash Flows	33
Selected Notes to the Consolidated Condensed Interim Financial Statement - Unaudited	34

DIRECTORS' REPORT TO THE MEMBERS

DIRECTORS' REPORT

We are pleased to present the consolidated interim financial information of the holding company for the three months ended September 30, 2019. These financial statements have been prepared in accordance with the requirements of the International Accounting Standard (IAS) 34 – 'Interim Financial Reporting' and the provisions of the directives issued under the Companies Act, 2017.

MARKET OVERVIEW

Pharmaceutical sales in Pakistan grew at a (2013-19) CAGR of 12%, driven by new molecule introductions and supported by underlying demographic trends of increasing affordability, rising population, higher life expectancy and increased incidence of chronic diseases. However, the pharmaceutical industry is experiencing a constant downward trend, due to high reliance of imported APIs, low per capita expenditure and low prices in terms of global environment.

The recent economic conditions have raised challenges on the industry as a whole. It is well established fact that the chemical industry of Pakistan has capacity constraints to develop basic components required for manufacturing drugs. Therefore, the industry resorts to import of raw materials. Due to this significant dependability, fluctuation in exchange rates coupled with stiff price regulations directly affect the product margins and consequent commercial feasibility. Pakistani rupee has experienced double-digit depreciation which has put the pharma industry under immense pressure.



OPERATING RESULTS

Searle group of companies have always focused on improving the lives of patients by offering quality healthcare solutions. We have built a firm growing position by putting the benefit of patients and stakeholders, our fundamental priority and are proud of the impact of our efforts.

During the period ended September 30, 2019, the holding company's financial performance was affected by the exchange rate fluctuations. However, despite the challenging economic conditions, Searle group of companies managed to continue its momentum.

Financial highlights are summarized below:

- Net sales of the Company grew by 13% to Rs 4.96 billion.
- Gross profit margin remained at 48%.
- Operating profit margin was 19%
- Profit before and after taxation was 17% and 11% respectively.

EARNINGS PER SHARE

Basic earnings per share after taxation for the period was Rs. 2.57 (2018: Rs. 3.18).

There is no dilution effect on the basic earnings per share of the holding company, as the holding company has no convertible dilutive potential ordinary shares outstanding as at September 30, 2019.

FUTURE OUTLOOK

Moving forward, we are focusing on enhancing the share of specialty generic branded portfolio and targeting differentiated products. It is also pertinent to mention that Searle has an organic pipeline of over 200 products in different stages of the regulatory approval process.

Further, due to overly regulated drug pricing mechanism, volatility in retail prices is a concern of paramount importance for us. Delays in new product approvals also pose key threats for the industry as a whole. However, with the change in recent political scenario, we will have to wait to assess the future economic trends and modify our strategies accordingly. For the longer run, Searle is focusing on emerging portfolios including, bio-similars, medical devices, nutraceuticals and genome sciences.

ACKNOWLEDGEMENT

At Searle group of companies, we all are emotionally motivated and willing to contribute enthusiastically on continuous basis. Same is the case with our partners, suppliers and customers, for which we are thankful and expect the same zeal and zest for future contribution. We assure, Searle will continue to work hard to provide long term sustainable growth to everyone associated with us.

For and on behalf of the Board

Syed Nadeem Ahmed Chief Executive Officer

(Lubar)

Zubair Razzak Palwala Director

Karachi : October 28, 2019

سرل گروپ ایک ایسا گروپ ہے کہ جس نے ہمیشداعلیٰ معیار کی ہیلتھ کیئر خد مات پیش کرنے کے ذریعے مریضوں کی زندگی وحالت کو بہتر بنانے ک کوشش کی ہے۔ہم نے مریضوں اور اسٹیک ہولڈرز کے لئے فوائد کو مذظرر کھتے ہوئے ایک متحکم ترقی کی پوزیشن حاصل کی ہے ہماری بنیا دی ترقیح یہی ہے اور ہم اپنی کوششوں کے بارآ ورہونے پرفخر کرتے ہیں۔

30 ستبر 2019 کوختم ہونے والی سہ ماہی کے دوران ہولڈنگ کمپنی کی مالیاتی کارکردگی زرمبادلہ کے زخوں میں اُ تارچڑھاؤک باعث متاثر ہوئی تاہم کٹھن اور چیلجنگ اقتصادی صورتحال کے باوجودسرل گروپ آفکیپنیز نے اپنا کاروبار بھر پورطریقے پرجاری رکھا۔

مالیاتی نکات مختصراً ذیل میں بیان کئے گئے ہیں

- کېنی کې خالص سيلز 13 فيصد تک بر هرکر 4.96 بلين رو په موگن -
 - مجموعی منافع کی شرح48 فیصد پر برقر ارد ہی۔
 - آ پربینگ منافع کی شرح 19 فیصد تھی۔
- منافع قبل از اور بعد از شیسیشن بالتر تیب 16 فیصد اور 11 فیصد رہا۔

آمدنى فيشيئر

بنیادی آمد نی اس مدت کیلئے فی شیئر بعدا ڈیکشین 2.57رو پر بنی (2018: 3.18روپے)۔ ہولڈ تگ کپنی کی بنیادی آمد نی فی شیئر پر براہ راست کو نی اثرات خاہز نہیں ہوئے کیونکہ ہولڈ تگ کپنی کے سمک مذشقل کی طاقت کی حامل نہ ہونے کے باعث عمومی شیئرز برطابق 30 ستیر 2019 برقر ارر ہے۔

مستقبل يرايك نظر

آ گے بڑھتے ہوئے ہم خصوصاً عمومی برانڈز کے پورٹ فولیو میں شیئر بڑھانے اور مختلف النوع پروڈکٹس کو ٹارگٹ کرر ہے ہیں۔ بیدواضح کرنا بھی ضروری ہے کہ ہرل 200 سے زائداً رگینک مصنوعات کوریگولیٹری منظوری کے خلف مراحل کے عمومی طریقہ کار سے گز رر ہاہے۔

مزید برآں ادویات کے نرخوں کے غیر منظم میکنزم کے باعث ریٹیل زخوں میں اتار چڑھا دیکھی ہمارے لئے تشویش کا ایک بڑا سبب ہے۔ نئ پروڈ کٹ کی منظوری میں تا خیر سے بھی محموقی طور پرصنعت کے لئے کلیدی خطرات سا منے آتے ہیں۔ تاہم جالیہ سیاسی صورتحال کی تبدیلی کے ساتھ ہم آنے والے معاشی ربحانات کا جائزہ لے رہے ہیں اور اس کے مطابق اپنی حکمت عملیوں میں تیدیلی لائیں گے۔ آنے والے سالوں میں سرل اکجرتے ہوئے پورٹ فولیونشمول بائیو۔ سمیلر ز،میڈیکل ڈیوائسز ، نیوٹراسیوٹیکڑ اور جنیوم سائٹسز پڑھموصی توجہ دے رہی ہے۔ **اظہار تشکر**

سرل گروپ آف کمپنیز میں ہم سب جذباتی طور برطحوط و تحرک ہیں اور مستقل بنیا دوں پر پُرعز م شراکت کے خواہ شمند میں ۔ای طرح ہمارے شراکت کار، سپلائرز اور صارفین، جس کیلئے ہم ان کے شکر گزار ہیں اورتو قع کرتے ہیں کہ ای کمکن کے ساتھ وہ مستقبل میں بھی شریک کارر ہیں گے۔ہم یقین دہانی کراتے ہیں کہ سرل اپنی انتہائی کوششیں جاری رکھ گی اورہم سے نسلک تما م شراکت کاروں نے لئے طویل مدتی بنیا دوں پر ترقی کی نئی منازل فراہم کی جائیں گی ۔

برائے اور پورڈ کی جانب سے

ليمر معمل الم ديررداق يال والا

flower? سدنديماحم جف الكّزيكثوآ فيسر

کراچی: ۲۸ اکتوبر۲۹۰۹ء

ڈ ائر یکٹر

ڈائر یکٹرز کی رپورٹ


ہم 30 ستمبر 2019 کو ختم ہونے والی 3 ماہ کی مدت کیلئے ہولڈنگ کمپٹی کی مجموعی عیوری مالیاتی معلومات پیش کرتے ہوئے خوشی محسوس کرتے ہیں۔ یہ مالیاتی حسابات انٹریشنل اکاؤنٹنگ اسٹینڈرڈ(IAS) 34 - ^دعیوری فنانٹل رپورٹنگ کی شرائط وضواط اوکپینز ایک 2017 *کے تحت* جاری کردہ ہدایات کی شقوں سے مطابق تیار کئے گئے ہیں۔

ماركيث كاجائزه

پاکستان میں فارماسیو ٹیکڑ کی فروخت (19-2013) میں 12 فیصد کے CAGR تک بڑھیں جس کی وجہ نے مالیکیو ل کا تعارف اوراستطاعت میں اضافے کے رجمانات، بڑھتی ہوئی آبادی، بلندتر زندگی کے امکانات اور مہلک و پیچیدہ امراض میں اضافہ تھا۔ اس کے باوجود فارماسیو ٹیکل کی صنعت مستقل طور پر نیچلر بتحان سے گزررہی ہے جس کی وجہ درآمد کر دہ APIs پرزیادہ انحصار، فی کس اخراجات میں کمی اور عالمی ماحول کی سطح پر کمتر نرخ ہیں۔

حالیہ اقتصادی صورتحال نے مجموعی طور پرصنعت کے لئے جیلیجز کھڑے کئے ہیں۔ یہ ایک جانی مانی حقیقت ہے کہ پاکستان کی نیمیکل انڈسڑ ی ادومایت کی تیاری کے لئے درکار بنیادی اجزاء تیار کرنے کی گلجائش کی حال نہیں ہے لہٰذاصنعت کو خام مال کی درآ مد پر انحصار کرنا پڑتا ہے۔اس انحصار کی وجہ سے زرمبادلہ بے نرخوں میں اُتار چڑھاؤ کے ساتھز خوں کی تحت ریگولیشنز براوراست پردڈ کٹ کے شرح منافع اور بعدازان تجارتی افادیت کو متاثر کرتی ہیں۔ پاکستانی روپے کی قدر حالیہ دنوں میں دونی میں کم ہوئی جس سے فار ماانڈ سڑرکی کو تحت دباؤ کا سامار کرنا پڑا ہے۔

آ پرينگ نتائج



ستمير	30	
2018	2019	
إروں ميں)	(روپے ہز	
4,380,366	4,962,130	آمدنی
(2,257,030)	(2,589,484)	فروخت كےاخراجات
2,123,336	2,372,646	محموعی آمدنی
(1,202,196)	(1,400,997)	آ پریٹنگ اخراجات
(49,833)	(58,800)	ديگرآ پريڻنگ اخراجات
39,287	49,400	ديگرآ مدنى
910,594	962,249	آ پریشز سے آمدنی
(99,442)	(143,040)	مالياتى اخراجات
811,152	819,209	منافعقبل ازئيكس
(130,378)	(264,593)	انكم كميك اخراجات
680,774	554,616	منافع بعداز شيسيشن

CONSOLIDATED CONDENSED INTERIM STATEMENT OF

FINANCIAL POSITION As at September 30, 2019

		(Un-audited) September 30, 2019	(Audited) June 30, 2019
ASSETS	Note	(Rupees	in '000)
Non-current assets			
Property, plant and equipment Investment properties - at cost Intangible assets Long-term loans and advances Long-term deposits	5	3,830,163 2,771,202 353,898 258 16,210 6,971,731	3,786,177 2,724,116 365,268 270 <u>13,624</u> 6,889,455
Current assets			
Inventories Trade receivables Loans and advances Trade deposits and short-term prepayments Interest accrued	6 7	3,272,303 7,283,006 2,990,526 117,948 5,604	2,953,902 6,209,817 2,944,181 91,074 2,970
Other receivables	8	881,930	787,859
Taxation - payments less provision Tax refunds due from government - Sales tax Cash and bank balances	9	902,220 39,350 57,714 15,550,601	1,000,760 59,527 262,054 14,312,144
Asset classified as 'Held for Sale'		75,500	75,500
Total assets		22,597,832	21,277,099
EQUITY AND LIABILITIES			
Share capital and reserves			
Share capital Unappropriated profit General reserve Share premium Revaluation surplus on property, plant and equipment Attributable to owners of	10	2,124,253 8,151,751 280,251 1,630,974 1,435,815	2,124,253 7,603,678 280,251 1,630,974 1,437,936
The Searle Company Limited - Holding Company Non-controlling interests		13,623,044 <u>450,801</u>	13,077,092 442,137
LIABILITIES		14,073,845	13,519,229
Non-current liabilities Long term borrowings Deferred tax liabilities Retirement benefit obligations		4,664 96,581 <u>57,164</u> 158,409	4,664 96,581 55,820 157,065
Current liabilities		,	101,000
Trade and other payables Borrowings Unpaid dividend Unclaimed dividend	11 12	4,642,116 3,565,202 110,667 47,593 8,365,578	3,520,230 3,922,277 110,667 47,631 7,600,805
Total liabilities		8,523,987	7,757,870
Contingencies and commitments	13		
Total equity and liabilities		22,597,832	21,277,099

The annexed notes from 1 to 22 form an integral part of this consolidated condensed interim financial information

Chie xecutive Officer

Walnah Valual

Director

Chief Financial Officer

CONSOLIDATED CONDENSED INTERIM STATEMENT OF PROFIT **OR LOSS AND OTHER COMPREHENSIVE INCOME** For the period ended September 30, 2019 - Unaudited

		Quarter ended		
		September 30, 2019	September 30, 2018	
	Note	(Rupees		
Revenue from contracts with customers	14	4,962,130	4,380,366	
Cost of sales		(2,589,484)	(2,257,030)	
Gross profit		2,372,646	2,123,336	
Distribution cost		(1,096,777)	(921,718)	
Administrative expenses		(304,220)	(280,478)	
Other operating expenses		(58,800)	(49,833)	
Other income	15	49,400	39,287	
Profit from operations		962,249	910,594	
Finance cost		(143,040)	(99,442)	
Profit before income tax		819,209	811,152	
Income tax expense		(264,593)	(130,378)	
Profit for the period		554,616	680,774	
Other comprehensive income		-	-	
Total comprehensive income		554,616	680,774	
Total comprehensive income is attributable to:				
Owners of the The Searle Company Limited - Holding Company Non-controlling interests		545,952 8,664 554,616	675,910 	
Basic and diluted earnings per share (Rupees)	16	2.57	(Re-stated) 3.18	

The annexed notes from 1 to 22 form an integral part of this consolidated condensed interim financial information.

ecutive Officer

patual

Director

Chief Financial Officer

CONSOLIDATED CONDENSED INTERIM STATEMENT OF **CHANGES IN EQUITY** For the period ended September 30, 2019 - Unaudited

		Attributable to the owners of the Holding Company							
		Capital reserves		Revenue reserves					
	Share capital	Share premium	Issue of bonus shares	Revaluation surplus on Property, plant & equipment	General reserve	Unappro- priated profits	Sub-Total reserves	Non- Controlling interest	Total
Balance as at July 01, 2018	1,847,177	1,630,974	-	675,001	280,251	6,566,207	9,152,433	451,963	11,451,573
Transferred from surplus on revaluation of fixed assets on account of incremental depreciation for the period (net of tax)	-	-	-	(279)	-	279 675.910	- 675.910	- 4.864	- 680.774
Total comprehensive income for the period	-		-		-	0/0,910	075,910	4,004	000,774
Balance as at September 30, 2018	1,847,177	1,630,974		674,722	280,251	7,242,396	9,828,343	456,827	12,132,347
Balance as at July 01, 2019	2,124,253	1,630,974		1,437,936	280,251	7,603,678	10,952,839	442,137	13,519,229
Total comprehensive income for the period						545,952	545,952	8,664	554,616
Transferred from surplus on revaluation of fixed assets - net of deferred taxation: - incremental depreciation for the period				(2,121)		2,121			
Balance as at September 30, 2019	2,124,253	1,630,974		1,435,815	280,251	8,151,751	11,498,791	450,801	14,073,845

The annexed notes from 1 to 22 form an integral part of this consolidated condensed interim financial information.

Hereff ieffexecutive Officer Chie

Caluate

Director

Chief Financial Officer

CONSOLIDATED CONDENSED INTERIM STATEMENT **OF CASH FLOWS** For the period ended September 30, 2019 - Unaudited

		September 30, 2019	September 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES	Note	(Rupees	s in '000)
Cash generated from operations Finance cost paid Income tax paid Increase in long-term deposits Decrease/(increase) in long-term Joans and advances	17	565,701 (99,623) (166,053) (2,586) 12	43,299 (77,432) (113,378) - (110,472)
Net cash generated from / (used in) operating activities		297,449	(257,983)
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment Sale proceeds on disposal of property,		(85,001)	(204,433)
Plant and equipment Payments for investment properties Purchase of intangible assets Purchase of investments -		2,450 (61,717) (408)	- (2,520) (1,114)
at fair value through profit or loss Proceeds from redemption of investments - at fair value through profit or loss Sale proceeds on disposal of investment properties Dividend income received		-	(16) 55,000 3,426 17
Net cash (used in) investing activities		(144,676)	(149,640)
CASH FLOWS FROM FINANCING ACTIVITIES			
Dividend paid Loan repaid		(38) -	(62) (10,000)
Net cash used in financing activities		(38)	(10,062)
Net increase / (decrease) in cash and cash equivalents		152,735	(417,685)
Cash and cash equivalents at beginning of the period		(3,450,223)	(2,118,818)
Cash and cash equivalents at end of the period	18	(3,297,488)	(2,536,503)

The annexed notes from 1 to 22 form an integral part of these condensed interim financial statements.

xecutive Officer

palua

Director

Chief Financial Officer

NOTES TO THE CONSOLIDATED CONDENSED INTERIM FINANCIAL STATEMENTS

For the period ended September 30, 2019 - Unaudited

1. LEGAL STATUS AND OPERATIONS

The Searle Company Limited (the Company) was incorporated in Pakistan as a private limited company in October 1965. In November 1993, the Company was converted into a public limited company. Its shares are quoted on the Pakistan Stock Exchange. The Company is principally engaged in the manufacture of pharmaceutical and other consumer products. The registered office of the Company is situated at 1st Floor, N.I.C. Building, Abbasi Shaheed Road, Karachi.

International Brands Limited is the holding company, which holds 56.60% shareholding in the Company.

Following are the subsidiary companies:

	Principal Effective place of %age of holding		
Listed Company		September 30, 2019	June 30, 2019
Unlisted Companies		74.19%	74.19%
 Searle Pharmaceuticals (Private) Limited Searle Laboratories (Private) Limited Searle Biosciences (Private) Limited IBL Identity (Private) Limited IBL Future Technologies (Private) Limited Nextar Pharma (Private) Limited 	≻ Pakistan	100.00% 100.00% 100.00% 100.00% 87.20%	100.00% 100.00% 100.00% 100.00% 87.20%

2. BASIS OF PREPARATION

These condensed consolidated interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting. The accounting and reporting standards as applicable in Pakistan for interim financial reporting comprise of:

- International Accounting Standard (IAS) 34, Interim Financial Reporting, issued by the International Accounting Standards Board (IASB) as notified under the Companies Act, 2017; and
- Provisions of and directives issued under the Companies Act, 2017

Where the provisions of and directives issued under the Companies Act, 2017 differ with the requirements of IAS 34, the provisions of and directives issued under the Companies Act, 2017 have been followed.

This consolidated condensed interim financial information does not include all information and disclosures required in the financial statements and should be read in conjunction with the financial statements of the Company for the year ended June 30, 2019.

2.1 Changes in accounting standards, interpretations and pronouncements

a) Standards, interpretations and amendments to published approved accounting standards that are effective and relevant

IFRS 9 'Financial instruments' - This standard replaces the guidance in IAS 39. It includes requirements on the classification and measurement of financial assets and liabilities; it also includes an expected credit loss model that replaces the current incurred loss impairment model.

34 Quarterly Report September 2019

IFRS 15 'Revenue from contracts with customers' - IFRS 15 replaces the previous revenue standards: IAS 18 Revenue, IAS 11 Construction Contracts, and the related interpretations on revenue recognition.

IFRS 15 introduces a single five-step model for revenue recognition and establishes a comprehensive framework for recognition of revenue from contracts with customers based on a core principle that an entity should recognise revenue representing the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

b) Standards, interpretations and amendments to published approved accounting standards that are not yet effective but relevant

The following are the new standards, amendments to existing approved accounting standards and new interpretations that will be effective for the periods beginning on or after July 1, 2019 that may have an impact on the financial statements of the Company.

IFRS 16 'Leases' - This standard is effective for periods beginning from or after January 1, 2019. IFRS 16 replaces the previous lease standard: IAS 17 Leases. It will result in almost all leases being recognised on the statement of financial position, as the distinction between operating and finance leases is removed. Under the new standard, an asset (the right to use the leased item) and a financial liability to pay rentals are recognised. The only exceptions are short term and low value leases.

Further, IFRS 9 'Financial Instruments' (previously applicable from annual periods beginning on or after July 1, 2018). This standard replaces the guidance in IAS 39. It includes requirements on the classification and measurement of financial assets and liabilities; it also includes an expected credit losses model that replaces the current incurred loss impairment model.

The management is in the process of assessing the impact of changes laid down by these standards on its financial statements.

3. SIGNIFICANT ACCOUNTING INFORMATION AND POLICIES

The accounting policies and method of computations adopted in the preparation of this consolidated condensed interim financial information are the same as those applied in the preparation of the financial statements for the year ended June 30, 2019.

4. ACCOUNTING ESTIMATES, JUDGEMENTS AND FINANCIAL RISK MANAGEMENT

The preparation of this consolidated condensed interim financial information in conformity with approved accounting standards requires management to make estimates, assumptions and use judgements that affect the application of policies and reported amounts of assets and liabilities and income and expenses. Estimates, assumptions and judgements are continually evaluated and based on historical experience and other factors, including reasonable expectations of future events. Revisions to accounting estimates are recognised prospectively commencing from the period of revision.

Judgements and estimates made by the management in the preparation of this consolidated condensed interim financial information are the same as those that were applied to financial statements as at and for the year ended June 30, 2019.

The Company's financial risk management objectives and policies are consistent with those disclosed in the financial statements as at and for the year ended June 30, 2019.

NOTES TO THE CONSOLIDATED CONDENSED INTERIM FINANCIAL STATEMENTS

For the period ended September 30, 2019 - Unaudited

		(Unaudited) September 30, 2019	(Audited) June 30, 2019
5.	PROPERTY, PLANT AND EQUIPMENT	(Rupees ir	́ '000)
	Operating assets - note 5.1	3 134 624	3 046 624

Operating assets - note 5.1	3,134,624	3,046,624
Capital work-in-progress - at cost	695,539	739,553
	3,830,163	3,786,177

5.1 Details of additions in operating assets including transfers from capital work-in-progress during the period are as follows:

	Additions (at cost)		Disposals (at net book value)	
	September 30, 2019	September 30, 2018 (Rupees	September 30, 2019 s in '000)	September 30, 2018
Building on leasehold land	43,112	26,451	, _	-
Plant and machinery	14,928	134,837	-	-
Furniture & fittings	-	399	-	-
Vehicles	-	-	(1,058)	-
Office equipment	41,592	29,263	-	-
	99,632	190,949	(1,058)	-

(Unaudited)	(Audited)
September 30,	June 30,
2019	2019
(Rupees in	'000)

6. TRADE RECEIVABLES

Considered good

- Export receivables, secured	439,894	307,294
- Due from related parties, unsecured - note 6.1	5,301,640	4,628,362
- Others, unsecured	<u>1,541,472</u> 7,283,006	<u>1,274,161</u> 6,209,817
Considered doubtful - others Less: Provision for doubtful debts	165,454 (165,454)	165,454 (165,454)
	7,283,006	- 6,209,817

6.1 These are stated net of amount payable to IBL Operations (Private) Limited, United Brands Limited and IBL Logistics (Private) Limited - associated companies amounting to Rs. 385.53 million (2019: Rs. 284.97 million), Rs. 15.54 million (2019: Rs. 15.36 million) and Rs. 1.01 million (2019: Rs. 1.01 million) respectively.

7. LOANS AND ADVANCES	(Unaudited) (Audited) September 30, June 30, 2019 2019 (Rupees in '000)	
 considered good Advances to: employees for operating activities employees against salaries suppliers against purchase of land against imports 	93,981 107,140 8,567 11,527 708,921 572,062 67,500 47,500 115,809 208,640 994,778 946,865	7 2))
Loans to International Brands Limited: - Short term Ioan - note 7.1 - Current portion of long term Ioan	1,946,118 49,630 1,946,118 49,630	3
Current portion long-term loans to employe	e 1,995,748 1,995,748 e <u>- 1,564</u> <u>2,990,526</u> <u>2,944,181</u>	1

7.1 This loan is repayable within 1 year and carries mark-up at the rate of 12 months KIBOR + 2% per annum. The said loan was approved in the extra ordinary general meeting of IBLHC, held on May 18, 2016 as per the requirements of section 208 of the repealed Companies Ordinance, 1984.

	(Unaudited) September 30, 2019	(Audited) June 30, 2019
8. OTHER RECEIVABLES	(Rupees in	1 'OOO)
Receivables from related parties Due from group companies:		
- IBL Operations (Private) Limited against		
mark-up on over due balance	26,642	26,642
rental income - International Brands Limited against	6,500	1,125
expenses rental income	2,939	7,472 25,538
 International Franchises (Private) Limited against 	2,000	20,000
rental income - United Retail (SMC-Private) Limited [formerly The Home Makers (SMC-Private) Limited]: against	609	1,094
rental income and expenses Trax Online (Private) Limited against - expenses	227,195	294,777
	175	175
IBL Frontier Market (Private) Limited against - expenses		
- expenses	25,882	25,882
	289,942	382,705
Due from other related parties:		
Surplus arising under retirement benefit fund	5,250	5,250
Descively a from other then related contine	295,192	387,955
Receivables from other than related parties Others, considered good	<u>586,738</u> 881,930	<u>399,904</u> 787,859

NOTES TO THE CONSOLIDATED CONDENSED INTERIM

FINANCIAL STATEMENTS For the period ended September 30, 2019 - Unaudited

9.	CASH AND BA	ANK BALANCE	ES	(Unaudited) September 30, 2019 (Rupees in	(Audited) June 30, 2019 '000)
	Cash in hand			<u> </u>	<u>6,342</u> 6,342
	Balances with b - current accou - saving accou	unts		53,555 11 53,566	252,889 2,823 255,712
10.	SHARE CAPIT			57,714	262,054
10.	Authorised shar				
	(Unaudited) September 30,	(Audited) June 30,		(Unaudited) September 30,	(Audited) June 30,
	2019	2019 of shares)		2019 (Rupees	2019
	300,000,000	300,000,000	Ordinary shares of Rs. 10 each	3,000,000	3,000,000
	Issued, subsc	ribed and paid	l up capital		
	(Unaudited) September 30, 2019 (Number	(Audited) June 30, 2019 of shares)			
	12,553,074	12,553,074	Shares allotted for consideration paid in cash	125,531	125,531
	24,000	24,000	Shares allotted for consideration othe than cash	240 er	240
	199,848,171	199,848,171	Shares allotted as bonus shares	1,998,482	1,998,482
	212,425,245	212,425,245		2,124,253	2,124,253

11.	TRADE AND OTHER PAYABLES	(Unaudited) September 30, 2019 (Rupees ir	(Audited) June 30, 2019 1 '000)
	Creditors Bills payable in foreign currency Royalty payable Accrued liabilities Payable to provident fund Advance from customers - unsecured Accrued mark-up Taxes deducted at source and payable to	1,706,053 1,035,152 16,503 1,217,021 9,801 63,038 152,890	1,259,513 716,426 23,966 866,018 14,717 88,603 109,473
	statutory authorities Workers' Profit Participation Fund Workers' Welfare Fund Advance against sale of land Other liabilities	76,813 188,514 28,798 73,500 74,033 4,642,116	104,163 149,417 26,000 73,500 88,434 3,520,230

12. SHORT TERM BORROWINGS

 Running finance under mark-up 		
arrangements - note 12.1	3,355,202	3,712,277
- Export re-finance	210,000	210,000
	3,565,202	3,922,277

12.1 The holding Company has entered into running finance under mark-up arrangements from various banks amounting to Rs. 4,175 million (June 30, 2019: Rs. 4,175 million) which include financing facilities obtained under Islamic mode amounting to Rs. 3,525 million (June 30, 2019: Rs. 3,525 million). The arrangements are secured jointly by registered mortgage of Rs. 589.44 million (June 30, 2019 : Rs. 589.44 million) of immovable property together with joint pari passu charge on all current assets of the Company to the extent of Rs. 4,071 million (June 30, 2019: Rs. 4,071 million) in favour of Standard Chartered Bank (Pakistan) Limited (the lead bank).

The rates of mark-up ranged between 13.34% to 13.96% (June 30, 2019: 6.9% to 12.7%) per annum.

13. CONTINGENCIES AND COMMITMENTS

13.1 Contingencies

13.1.1 There has been no significant change in the status of contingencies as reported in the note 24 and 32.3 of annual audited consolidated financial statements of the Company for the year ended June 30, 2019.

13.2 Commitments

13.2.1 The facility for opening letters of credit and guarantees as at September 30, 2019 amounted to Rs. 2,180 million (June 30, 2019: Rs. 2,111 million) of which the amount remaining unutilised as at period end amounted to Rs. 221 million (June 30, 2019: Rs. 318 million).

NOTES TO THE CONSOLIDATED CONDENSED INTERIM FINANCIAL STATEMENTS

For the period ended September 30, 2019 - Unaudited

13.2.2 Future rentals payable against operating lease arrangements

Further, the Company has also entered into lease arrangements with Myplan Pharmaceuticals (Private) Limited and S. A. Pharma, a pharmaceutical concern, respectively, for a period of 20 years for land, building and plant and machinery located at Lahore.

The details of future rentals payable over the lease period are as follows:

	(Unaudited) September 30, 2019	(Audited) June 30, 2019
	(Rupees i	
Not later than one year	27,918	28,868
Later than one year but not later than five years	136,611	137,571
Later than five years	88,727	93,959
	253,256	260,398

14. REVENUE FROM CONTRACTS WITH CUSTOMERS

	(Unaudited) September 30, 2019	(Unaudited) September 30, 2018
		s in '000)
Gross sales		,
Local sales	4,743,080	4,196,504
Export sales	628,782	488,185
	5,371,862	4,684,689
Toll manufacturing	71,854	87,836
ion manadatan ng	5,443,716	4,772,525
Sales tax	(67,299)	(28,847)
	5,376,417	4,743,678
Less:		
Discounts, rebates and allowances	315,173	307,781
Sales returns	99,114	55,531
	414,287	363,312
	, -	,
	4,962,130	4,380,366

15.	OTHER INCOME	(Unaudited) September 30, 2019 (Rupees	(Unaudited) September 30, 2018 s in '000)
	Income from financial assets		
	Realised gain on investments - at fair value through profit or loss Unrealised gain on investments - at fair	-	73
	value through profit or loss		226
	Interest on loan to International Brands Limited Dividend income	7,882	5,416 17
		7,882	5,732
	Income from non - financial assets		
	Gain on disposal of property, plant and	1,392	_
	equipment Exchange (loss) / gain	1,536	97
	Rental income from investment properties	31,913	30,263
	Others	6,677	3,195
		41,518	33,555
		49,400	39,287

16. BASIC AND DILUTED EARNINGS PER SHARE

Profit for the year (Rupees in '000)	537,952	675,910
Weighted average number of outstanding shares at the end of the period (in thousand) - Restated	212,425	212,425
Basic and diluted earnings per share (Rupees) - Restated	2.57	3.18

NOTES TO THE CONSOLIDATED CONDENSED INTERIM

FINANCIAL STATEMENTS For the period ended September 30, 2019 - Unaudited

17.	CASH GENERATED FROM OPERATIONS	September 30, September 30, 2019 2018 (Rupees in '000)		
	Profit before income tax	819,209	811,152	
	Add / (less): Adjustments for non-cash charges and other items Depreciation Gain on disposal of property, plant and equipment - net Amortisation Provision for retirement benefits obligation Unrealised gain on investments - at fair value through profit or loss	54,588 (1,392) 11,778 1,344 -	58,606 - 11,093 899 (142)	
	Realised gain on investments - at fair value through profit or loss Dividend income Interest income-net Finance cost	- (2,632) 143,040	(73) (17) (5,416) 99,442	
	Profit before working capital changes	1,025,935	975,545	

Effect on cash flow due to working capital changes

(Increase) / decrease in current assets

Inventories	(318,401)	51,610
Trade receivables	(1,073,189)	(939,768)
Loans and advances	(46,345)	(429,998)
Trade deposits and short-term prepayments	(26,874)	(16,894)
Tax refunds due from government - Sales tax	20,177	(15,720)
Other receivables	(94,071)	(159,255)
		(100,200)
	(1,538,703)	(1,510,025)
Increase in current liabilities	())	() / /
Trade and other payables	1,086,469	577,779
	1,086,469 -	577,779
Cash generated from operations	565,701	43,299
CASH AND CASH EQUIVALENTS		
Cash and bank balances - note 9	57,714	72,908
		· · · · · ·
Short term running finances - note 12	(3,355,202)	(2,609,411)

(3,297,488)

(2,536,503)

18.

19. SEGMENT INFORMATION

The financial information regarding operating segments is as follows:

	Pharma	ceutical	Cons	umer	То	tal
·	Sept' 30 2019	Sept' 30 2018	Sept' 30 2019 (Rupees	Sept' 30 2018 in '000)	Sept' 30 2019	Sept' 30 2018
Segment revenue	3,973,646	2,501,820	988,484	1,878,546	4,962,130	4,380,366
Segment result	922,242	910,064	49,407	11,076	971,649	921,140
Unallocated income and expenses						
Other expenses					(58,800)	(49,833)
Other income					49,400	39,287
Finance cost					(143,040)	(99,442)
Profit before taxation					819,209	811,152
Income tax expense					(264,593)	(130,378)
Total comprehensive income					554,616	680,774
	Pharma	ceutical	Cons	umer	Το	tal
	Sept' 30 2019	June 30, 2019		June 30, 2019 in '000)	2019	June 30, 2019
Segment assets and liabilities						
Segment assets	821,768	833,052	63,916	63,916	885,684	896,968
Unallocated assets					21,712,148	13,229,777
Total assets					22,597,832	14,126,745
Unallocated liabilities					8,523,987	5,779,119
Total liabilities					8,523,987	5,779,119

NOTES TO THE CONSOLIDATED CONDENSED INTERIM

FINANCIAL STATEMENTS For the period ended September 30, 2019 - Unaudited

20. TRANSACTIONS WITH RELATED PARTIES

The following transactions were carried out with related parties during the period:

		September 30, 2019	September 30, 2018		
Nature of relationship	Nature of transactions	(Rupees in '000)			
Holding company	 Corporate service charges Rent income Income from provision of amenities 	60,000 1,669 1,270	48,000 2,276 1,905		
Associated companies	 Revenue Salaries and wages Purchases Carriage and duties Discounts claimed Rent expense Rent income Stock claims Internet services Architect fee Income from Provision of Amenities Donations Purchases of ERP Software/Hardware Incentive on Searle Focus Prooducts Repair & maintenance Merchandising Services Others 	3,091,743 70 245 1,518 76,265 2,547 16,504 18,778 281 2,375 9,474 4,296 696 859 2,203 3,400	2,775,860 130 843 10,512 80,818 1,066 15,268 42,030 1,109 1,906 5,300 25,072 1,616 18,653		
Staff retirement benefits	- Contributions to Provident				
K	- Benefits paid	29,213 12,375	26,174 37,429		
Key management employees compensation	- Salaries and other				
componed on	- Contributions to	41,978	42,090		
	- Directors' fees	3,556	4,212		
	- Sale of goods	24			

The status of outstanding balances with related parties as at September 30, 2019 is 20.1 included in the respective notes to the financial statements. These are settled in the ordinary course of business.

CORRESPONDING FIGURES 21.

Corresponding figures have been rearranged for better presentation and comparison purpose, wherever considered necessary. However, there is no material reclassification.

DATE OF AUTHORISATION FOR ISSUE 22.

This consolidated condensed interim financial information was approved and authorised for issue by the Board of Directors of the Company on October 28, 2019.

Chief Financial Officer

Chief Executive Officer

Director



THE SEARLE COMPANY LIMITED

1st Floor, N.I.C.L. Building, Abbasi Shaheed Road, Karachi-75530 URL: www.searlecompany.com

infini.com.pk 35301852